The Cell and Gene Therapy Drug Delivery Devices Market Size is valued at 134.0 Thousand in 2022 and is predicted to reach 515.0 Thousand by the year 2031 at a 16.2 % CAGR during the forecast period for 2023-2031.
Key Industry Insights & Findings from the Report:
- Increasing prevalence of genetic disorders & chronic diseases driving cell and gene therapy drug delivery devices market.
- An increasing number of FDA approvals for cell & gene therapies & their clinical trials driving cell and gene therapy drug delivery devices market.
- North America dominated the market and accounted for a global revenue share in 2023.
- The key challenge for the cell and gene therapy drug delivery devices market is the high costs associated with the manufacturing of these therapies.
The demand for cell and gene therapy drug delivery devices market is enhancing as there is an increase in the number of patients suffering from cancer, diabetes, and other chronic diseases. Therefore, there is a high need of developing affordable and cost-effective cell and gene therapies. Cell and gene therapy is a clinical procedure of modifying genetic material for the treatment of various diseases. Drug Delivery devices have the capacity to perform multiple functions with the highest degree of smartness. Cell and Gene Therapy Drug Delivery Devices are beneficial in the treatment of respiratory diseases, diabetes, and other cardiovascular disorders.
Spreading awareness regarding the benefits of cell and gene therapy drug delivery devices is expected to propel the product demand. Furthermore, fast adoption of advanced technologies, an invention of new devices according to patient’s requirements, increasing government initiatives for research and development of new therapies and devices, high prevalence of chronic diseases, rising number of clinical trials, and creation of smartphone applications will also help to upscale this market. However, the high cost of manufacturing systems, lack of standard therapy protocols, complex procedures, and shortage of skilled professionals are limiting the growth of this market.
Competitive Landscape
Some of The Key Players in The Cell and Gene Therapy Drug Delivery Devices Market:
- Amgen Inc.
- Bausch & Lomb Incorporated.
- Becton, Dickinson and Company
- Bluebird bio, Inc.
- Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
- Dendreon Pharmaceuticals LLC.
- Helixmith Co., Ltd (ViroMed Co., Ltd)
- Human Stem Cells Institute
- Kite Pharma, Inc.
- Kolon TissueGene, Inc.
- Novartis AG
- Orchard Therapeutics plc.
- Pfizer, Inc.
- Renova Therapeutics
- Spark Therapeutics, Inc.
- uniQure N.V.
- Vericel Corporation
- Other Prominent Players
Market Segmentation
The cell and gene therapy drug delivery devices market can be segmented on the basis of products, Commercialized Drugs, and Regions. On the basis of products, the market can be sub-divided into Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags. On the basis of Commercialized Drugs, the market is sub-segmented into Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis. Commercialized Drugs segment is expected to dominate this market, as these drugs are modified and prepared according to patient’s requirements. In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Out of these regions, North America is expected to dominate the market over the forecast period (2019-2031).
Recent Developments:
- In May 2024, Bluebird Bio, Inc. successfully conducted the initial commercial cell collection for LYFGENIA, an FDA-approved gene therapy for sickle cell disease that was authorized in December 2023. LYFGENIA is the gene therapy that has undergone the most extensive research for sickle cell disease, and it has been examined for the longest period of time compared to other treatments in this field.
The Cell and Gene Therapy Drug Delivery Devices Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 134.0 Thousands |
|
Revenue Forecast In 2031 |
USD 515.0 Thousands |
|
Growth Rate CAGR |
CAGR of 18.0 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Thousands and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, By Commercialized Drugs |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bausch & Lomb Incorporated., Amgen Inc., Becton, Dickinson and Company, Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC., Bluebird bio, Inc., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., Kolon TissueGene, Inc., Vericel Corporation, uniQure N.V., and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
